CLINICAL_TRIALS
trial_result
· 2012-12-06
Clinical Trial Update: Phase 1 Study of MDX-1401 in Patients With CD30-positive Refractory/Relapsed Hodgkin's Lymphoma [Phase 1]
Summary
A Phase 1 study evaluating MDX-1401 in patients with CD30-positive relapsed or refractory Hodgkin lymphoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Hodgkin's Lymphomas | Phase 1 | Status: COMPLETED